Overview

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide actionable insights, helping physicians make informed treatment decisions and identify gaps in patient care. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on precision medicine, aiming to improve healthcare delivery and drug development.

💡 Want to apply to Tempus?

You have ways to get a Tempus referral from your network.

Get referrals →

Simplify's Take

What believers are saying

• Tempus' partnership with AstraZeneca and Pathos AI boosts oncology model development.
• Acquisition of Deep 6 AI expands Tempus' network to 750 provider sites.
• Projected 78% revenue growth by 2025 indicates strong market potential.

What critics are saying

• Data privacy challenges arise from integrating Deep 6 AI's extensive network.
• Partnership with AstraZeneca and Pathos AI may face data-sharing protocol issues.
• Rapid expansion may strain Tempus' operational capabilities and affect service delivery.

What makes Tempus unique

• Tempus uses AI to analyze clinical and molecular data for precision medicine.
• Their platform aids drug development by discovering novel targets and evaluating treatments.
• Tempus' pan-cancer organoid platform enhances personalized therapeutic opportunities for cancer patients.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$1867.3M

Above

Industry Average

Funded Over

11 Rounds

Notable Investors:

New Enterprise Associates

Notable Investors:

New Enterprise Associates

$300,000,000

Post IPO Debt

Feb 2025

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Debt Funding Comparison

Coming Soon

View all funding stages